DiscGenics Treats First Patient in IDCT Trial

The first patient has been treated in DiscGenics' Phase I/II U.S. clinical trial of IDCT injection to treat mild to moderate degenerative disc disease.

IDCT is an allogeneic cell therapy comprising Discogenic Cells and a viscous scaffold. During treatment, a dose of IDCT is injected percutaneously into the disc. The prospective, randomized,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us